home / stock / sny / sny articles

SNY Articles, Sanofi - From 07/17/24

Stock Information
Company Name: Sanofi
Stock Symbol: SNY
Market: NASDAQ
Website: sanofi.com
Menu
SNY SNY Quote SNY Short SNY News SNY Articles SNY Message Board
Get SNY Alerts

News, Short Squeeze, Breakout and More Instantly...
European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment | Benzinga

The European Commission faced criticism from Europe’s second-highest court regarding transparency issues surrounding COVID-19 vaccine contrac...
Senate To Review Novo Nordisk's Levemir Insulin Discontinuation | Benzinga

Democratic U.S. Senate aides will meet with executives from Novo Nordisk A/S (NYSE:NVO) on Tuesday to discuss the ramifications of the company̵...

Sanofi's $20B Consumer Health Unit Sale: Goldman Sachs, Morgan Stanley Line Up $6.5B Financing | Benzinga

Goldman Sachs Group Inc. (NYSE:GS) and Morgan Stanley (NYSE:MS) are reportedly preparing to arrange more than $6.5 billion (6 billion euros) in deb...

Bernie Sanders Targets High Prices of Ozempic and Wegovy In US | Benzinga

Senator Bernie Sanders expressed confidence that Novo Nordisk A/S (NYSE:NVO) can be persuaded to reduce the U.S. prices of its popular weight-loss ...
Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data | Benzinga

On Wednesday, the European Medicines Agency (EMA) approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chr...

Heartburn Drug Zantac Litigation: GSK And Other Pharma Giants Face Trial Over Cancer Claims | Benzinga

A Delaware judge has dismissed a request from GSK Plc (NYSE:GSK) and other pharmaceutical companies to appeal a ruling that allows over 70,000 laws...

Sanofi Nears Decision on $1.6B Upgrade For Frankfurt Insulin Plant | Benzinga

French drugmaker Sanofi is poised to commit between 1.3 billion euros and 1.5 billion euros ($1.4 billion – $1.6 billion) to enhancing its in...
Denali Outperforms Industry in 3 Months: Here's Why | Benzinga

Denali Therapeutics Inc. (NASDAQ: DNLI) is having a good run in 2024. Shares of this biopharmaceutical company have risen 11.9% in the past three m...

First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product | Benzinga

On Wednesday, the FDA approved Verona Pharma plc’s (NASDAQ:VRNA) Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructiv...

Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi | Benzinga

- Sanofi to invest $40 million at an as-converted price of $7.44 per share of common stock- - Sanofi to receive an exclusive right of first negoti...
Previous 10 Next 10